ABSTRACT
STATEMENT OF TRANSLATIONAL RELEVANCE:
One proposed but unproven mechanism of action (MoA) of the monoclonal antibody (mAb) trastuzumab is induction of antibody dependent cellular cytotoxicity, in which the Fc portion of trastuzumab engages with the Fc-gamma receptor (FcγR) on immune effector cells leading to tumor cell destruction. We sought to determine whether differences in FcγR affinity resulting from two single nucleotide polymorphisms in FcγRIIIa and FcγRIIa impact the clinical outcome of trastuzumab-treated patients. An association between FcγR genotype and outcome was reported with other mAb's for lymphoma and colon cancer. Such an association would provide evidence that the immune system plays a role in the MoA of trastuzumab. These results also impact the future practice of cancer medicine because a positive association would support the development of engineered antibodies with an increased affinity for FcγR and would support the use of genotyping to preselect patients most likely to respond to trastuzumab. 
INTRODUCTION:
Amplification of the HER2 gene is a key driver in the pathogenesis and biological aggressiveness of approximately 25% of breast cancer. 1 Trastuzumab, a humanized anti-HER2 monoclonal IgG1 antibody is known to significantly improve clinical outcome for both early and advanced HER2-positive breast cancer. [2] [3] [4] Although the mechanisms of action of trastuzumab are not completely understood, 5 preclinical models suggest that growth factor receptor blockade results in critical changes in growth signaling pathways including downregulation of PI3K-AKT signaling leading to decreased cell proliferation and cycle arrest. 6 Other mechanisms suggested from preclinical studies also include inhibition of extracellular domain shedding, decreased angiogenesis, and inhibition of DNA repair. 7, 8 Therapeutic antibodies of the IgG1 subtype can also mediate antibody dependent cell mediated cytotoxicity (ADCC). This potential mechanism involves antibody binding to HER2 on the surface of tumor cells, followed by the Fragment C (Fc) portion of the antibody engaging Fcgamma receptors (FcγR) expressed on immune effector cells, ultimately resulting in target cell lysis. Preclinical evidence for this mechanism in trastuzumab efficacy was demonstrated in immunodeficient mice bearing human breast cancer xenografts. 9 Furthermore, afucosylated trastuzumab with enhanced affinity to FcγR exhibits greater anti-tumor activity in xenograft models than native trastuzumab. Two studies reported an association between at least one FcγR polymorphism and clinical outcome. 19, 20 The other study revealed no such association. 21 The aim of this study was to further clarify whether FCGR3A and FCGR2A genotypes are correlated with clinical outcome in trastuzumab-treated patients. Such an association would substantiate a role for FcγR-bearing immune effector cells in the anti-tumor activity of trastuzumab.
PATIENTS & METHODS

FcγR polymorphism genotyping
DNA was purified from serum and whole blood samples using a QIAamp DNA Blood Mini Kit (QIAGEN, CA), and used for nested PCR amplification of regions containing the FCGR3A 158 V/F and FCGR2A 131 H/R SNPs using primers listed in Supplemental 
Patient Population
Adjuvant Breast Cancer Cohort (BCIRG-006)
Genomic DNA from serum and whole blood samples was obtained from patients treated in the Breast Cancer International Research Group (BCIRG)-006 study. 23 This adjuvant study compared two trastuzumab-containing arms to a non-trastuzumab containing control arm for treatment of HER2-positive, early breast cancer. In total, 3,222 patients were randomly assigned to one of three treatment arms: (1) AC-T: four cycles of q3 weekly doxorubicin (A, 60 mg/m2 IV) plus cyclophosphamide (C, 600 mg/m2 IV) followed by four cycles of q3 weekly docetaxel (T, 75 mg/m2 IV), (2) AC-TH: AC-T plus trastuzumab (H, 8 mg/kg IV loading dose with first dose of docetaxel followed by 6 mg/kg q 3 weeks for 1 year) or (3) TCH: six cycles of q3 weekly docetaxel, carboplatin (C, AUC 6), trastuzumab (as above, for 1 year FCGR2A. Approximately 860 samples sequenced were from whole blood, and the success rate was over 99% for both polymorphisms from these specimens. The remainder of patients (over 400) only had serum provided. The concentration of DNA is lower in serum compared with whole blood, thus making it technically more challenging to extract an adequate amount of DNA for reliable sequencing from serum. The vast majority of sequencing failures were from serum samples. That said, the fail rate in serum for FCGR3A was higher than that for FCGR2A so there may be a contributing factor that depends on the primers. Due to high homology with FCGR3B, there are unfortunately very limited options for designing primers specific for FCGR3A. Both the early and advanced disease cohort studies were conducted according to institutional review board/ethics committee-approved protocols. Informed consent was obtained from all participating patients. REMARK guidelines 24 were followed in the reporting of these results.
Research. 
Statistical Methods and Association Testing
For the adjuvant cohort, DFS was calculated from the date of randomization to the date of disease recurrence as declared by the treating physician, or death from any cause. This retrospective data analysis was based on the third planned analysis of the BCIRG-006 study. 23 For the advanced disease cohort, PFS was calculated from start of first exposure to trastuzumab (in the metastatic or locally recurrent setting) to the time of disease progression or death from any cause. DFS and PFS curves were estimated using the method of Kaplan-Meier.
The effect of trastuzumab and the prognostic impact of genotype were assessed using the logrank test. The predictive impact of genotype on the effect of trastuzumab was assessed through interaction tests in Cox regression models.
SNPStats software (http://bioinfo.iconcologia.net/SNPstats) 25 
RESULTS
Patient Characteristics
Adjuvant Breast Cancer Cohort
The prognostic clinical and pathological features of patients according to treatment arm are shown in Figure 1) indicating that trastuzumabbased therapy significantly extends DFS compared with chemotherapy alone. 23 The clinical and tumor characteristics of the patients genotyped in our study compared to the patients who were not genotyped are shown in Supplemental Table 2. In the subset of patients genotyped in our study (N=1,286), a less robust improvement in DFS was observed for patients treated with trastuzumab compared to control arm therapy (combined trastuzumab-arms vs AC-T HR=0.842, Figure 2) . Stratified analysis demonstrated that this may be due to genotyped patients in the trastuzumab arms numerically having worse prognostic features than patients in the AC-T arm (Table 1) . When stratified for age, node status, hormone receptor status, size and surgery type, the hazard ratio in favor of trastuzumab was consistent with that of the overall patient population and statistically significant (HR=0.74, P=0.036) (Supplemental Figure 3) . Baseline patient characteristics by genotype for this adjuvant cohort are shown in Table 2 .
P=0.1925) (Supplemental
Advanced Disease Breast Cancer Cohort
Patient characteristics by genotype in this 53-patient cohort are shown in Supplemental Table   3 . HER2-overexpression/amplification was verified in 50 and was unknown in three participants.
Tumors were positive for one or both hormone receptors in 70% (N=37) of patients, negative for both in 23 % (N=12) and unknown in 8% (N=4). A total of 42% of patients were postmenopausal.
Tumor grade was grade 1 in 2%, grade 2 in 30%, grade 3 in 53% and unknown in 15% of patients. Visceral metastases were present in 66% of participants. Of the 53 patients, 43 had not received prior chemotherapy and ten had received one to four previous chemotherapy regimens. In terms of specific trastuzumab-based regimens received by patients, 18 (34%) received trastuzumab alone, 28 (53%) received single-agent chemotherapy plus trastuzumab and seven (13%) received doublet (taxane-platinum) chemotherapy plus trastuzumab.
Genotype and Allele Frequencies
Adjuvant Breast Cancer Cohort
The frequency of FCGR3A/2A genotypes did not differ significantly among treatment arms ( Table 2) . We observed a minor allele frequency of 0.34 and 0.48 for FCGR3A and FCGR2A, respectively. The frequencies of FCGR3A genotypes deviated from HWE whereas the genotype distributions for FCGR2A were in conformity with the HWE assumptions (Supplemental Table   4 ). The influence of genotyping errors on the observed deviations from HWE for FCGR3A were ruled out or minimized since the genotyping data from two independent technology platforms (see methods) were concordant. We do not have genotype data from apparently healthy control subjects to assess conformity with HWE assumptions in a case-control setting to suggest putative association of this locus with breast cancer risk or the associated phenotypes, thus limiting the interpretability of our findings. We nonetheless included this allele for further analysis to permit comparisons with the previously reported, smaller studies. 19, 20 The LD (D'=0.32) we observed between FCGR2A and FCG3RA were entirely concordant with those previously reported in the literature.
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FcγR Polymorphisms and Outcome
Adjuvant Breast Cancer Cohort
Baseline patient and tumor characteristics did not differ significantly between the FCGR3A V/V, V/F or F/F polymorphism groups, nor between FCGR2A H/H, H/R or R/R groups ( Table 2 ). In the population of patients genotyped who were in the non-trastuzumab containing control arm (Figure 3) , the difference did not reach significance in any genotype, and the tests for interaction between trastuzumab and genotype were all non-significant.
Advanced Disease Breast Cancer Cohort
In the 53-patient advanced disease cohort, baseline prognostic features including age, tumor grade and disease free interval did not differ significantly between the three FCGR3A genotypes or the three FCGR2A genotypes (Supplemental Table 3 distribution of the FCGR3A 158V/F genotype was detected among 63 patients who achieved an objective response and those that had progressive disease. 21 Conversely, a subsequent study by Musolino and colleagues reported improved response rates and PFS for those patients with FCGR3A V/V and, to a lesser extent, FCGR2A H/H genotypes among 54 patients with HER2-positive metastatic breast cancer who received trastuzumab and taxane. 19 Tamura and FCGR2A genotypes and DFS was detected in a cohort of 1,286 patients treated with trastuzumab-based therapy in early breast cancer. Moreover, to expand this study to advanced disease, the retrospective analysis of a cohort of 53 women treated with trastuzumab-based therapy for metastatic breast cancer was performed and also revealed no significant correlation between FCGR3A and FCGR2A genotypes and PFS. While these data do not completely rule out the possibility that trastuzumab acts in part via ADCC, it does suggest that any differences in Fc-FcγR affinity attributed to the SNP's tested does not result in detectable differences in clinical outcome. We acknowledge that these data are limited by the fact that only 38% of the Research.
on April 14, 2017. © 2012 American Association for Cancer clincancerres.aacrjournals.org Downloaded from patients enrolled in the BCIRG-006 study were genotyped. Thus it is not possible to generalize conclusions originating from the genotyped subset to the entire BCIRG-006.
The trastuzumab benefit in this study appeared less robust in the adjuvant cohort compared to the benefit seen in the overall BCIRG-006 study population, most likely due to the fact that random sampling of study patients for genotyping could not be performed. This was because only those patients who provided informed consent and had separate blood/serum samples sent into the centralized laboratory for biomarker testing were evaluated. As a result, the sample in which FCGR3A/2A genotyping was performed was not representative of the entire patient population. In fact, in this sample, the lower benefit of trastuzumab may have been due to the imbalance in poorer than average prognostic features of trastuzumab-treated patients consenting to provide samples in this sub-study. However, stratified analyses adjusting for known prognostic factors support a statistically significant trastuzumab benefit of the same magnitude in the current cohort as in the overall population. That said, we cannot completely exclude a contribution of FCGR polymorphisms to the trastuzumab-treated patient outcomes.
Our results differ from those of Musolino et al, 19 and Tamura genotypes on outcomes appears to be diminished with concurrent chemotherapy. 28 On the other hand, the majority (87%) of breast cancer patients in our advanced disease breast cancer The two receptor polymorphisms considered in this study did not show a significant association with treatment outcomes. The minor allele frequencies and LD between these markers are consistent with previous findings. 19, 22 This is the largest analysis evaluating the association between 
